Since 2010, the coalition of twelve PDPs represented in this report have delivered nearly 80 new health technologies—treatments, vaccines, diagnostics, vector controls, and devices.

The PDPs in this coalition have nearly 300 potential new technologies in their pipelines, with more than 100 of those products in late-stage development.

To maximize impact, PDPs closely and continuously engage with local communities, care providers, researchers, and policy makers to ensure they are designing products for use in the settings where they are most needed, which are often low-resource environments.

The products that PDPs develop provide tremendous value for money and a strong return on investment. PDPs are consistently able to develop products at costs below that of the private sector.

PDPs have performed clinical research at more than 700 sites in nearly 100 countries, mostly in LMICs.

The development of products in PDPs’ portfolios, such as improved vaccines, treatments, diagnostics, and vector controls for tuberculosis, malaria, and HIV/AIDS, and improved tools for women’s and children’s health is a necessary precondition for universal health coverage and the achievement of: SDGs 1, 3, 5, 8, 10, and 17.

The capabilities of PDPs are not limited to poverty-related diseases. PDPs have mobilized to contribute to the global response to the COVID-19 pandemic by developing vaccine and monoclonal antibody candidates, providing chemical libraries to be tested for potential efficacy against SARS-CoV-2, and applying drug discovery techniques to aid in COVID-19 product research.

PDPs require stable long-term funding and investment across every stage of the research process To fully unlock the potential of PDPs, increased investments are needed from all parties and sectors, including BRICS and low- and middle-income countries.

Inconsistent, complex, and sometimes slow processes for earning approval and registration of new products in all countries are a significant challenge to ensure they are widely and equitably available. Relieving these barriers can also serve as a financial incentive for donors and product developers, resulting in a quicker and larger health impact and return on investment.

Accelerating and expanding access to new products requires dedicated investment and creative and multi-sectored partnerships. With more products approaching and reaching the market than ever before, the need to invest in access is increasingly critical and urgent.